Form 4: Pacira CFO Shawn Cross Executes Stock Option Plan

Pacira BioSciences CFO Shawn Cross exercised options and sold 12,941 shares under a pre-established Rule 10b5-1 trading plan.

Summary

• CFO Shawn Cross exercised stock options for 12,941 shares at a strike price of $16.45.
• The acquired shares were subsequently sold at a weighted average price of $25.16 per share.
• The transactions were executed on April 23, 2026, pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2025.
• Following these transactions, the reporting person maintains direct ownership of 105,341 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was pre-planned and represents standard executive equity management.

Positives

• The transaction was conducted under a pre-planned Rule 10b5-1 trading plan, indicating a systematic approach to equity management rather than reactive selling.
• The CFO retains a significant equity stake of 105,341 shares, aligning interests with shareholders.

Negatives

• The transaction represents a divestment of equity by a key member of the executive leadership team.

Risks

• Future share price volatility may impact the value of remaining holdings.
• Reliance on Rule 10b5-1 plans does not eliminate the potential for negative market perception regarding insider selling.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard practice for executives in the biotechnology sector to manage personal liquidity and tax obligations, and is generally viewed as neutral by the market.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to avoid potential conflicts of interest or accusations of insider trading.
• The scale of the sale relative to the total holdings is consistent with typical executive compensation liquidation patterns observed in mid-cap biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as the sale was executed through a pre-arranged plan.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Pacira BioSciences, PCRX, Insider Trading, Form 4, CFO, Equity Compensation